Legend Biotech Corporation (Legend), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that it has raised $150.5 million in Series A financing. New investors included Hudson Bay Capital Management LP, Johnson & Johnson Innovation - JJDC, Inc., Lilly Asia Ventures, Vivo Capital and RA Capital Management.

At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication. The spark of hope is lit. At Legend Biotech, we're using that hope to ignite the future of CAR-T cell therapy.